Danaher (NYSE:DHR) Announces Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Danaher (NYSE:DHR) issued its quarterly earnings results on Tuesday. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14, Briefing.com reports. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the firm posted $2.02 earnings per share. The business’s quarterly revenue was up 3.1% compared to the same quarter last year.

Danaher Stock Performance

NYSE DHR opened at $255.35 on Thursday. The company has a fifty day moving average price of $270.43 and a 200-day moving average price of $260.43. The firm has a market cap of $189.13 billion, a price-to-earnings ratio of 43.39, a PEG ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher has a 1 year low of $182.09 and a 1 year high of $281.70.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock valued at $8,400,897 over the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on DHR. KeyCorp upped their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. Barclays reduced their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday. The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reduced their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.